{
    "clinical_study": {
        "@rank": "80472", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be placed on 3 capsules a day of placebo (1000 mg of ethyl oleate 3 capsules a day) taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal."
            }, 
            {
                "arm_group_label": "Omega-3 free fatty acids", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be placed on 3 capsules a day of Omega 3 free fatty acids taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1000 mg of a \u03c93 FFA preparation containing 675 mg EPA and 300 mg DHA."
            }
        ], 
        "brief_summary": {
            "textblock": "Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus\n      subjects downregulate pro-neoplastic and pro-inflammatory pathways in the esophagus to\n      anti-inflammatory pathway?"
        }, 
        "brief_title": "Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Barrett's Esophagus", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Barrett Esophagus", 
                "Inflammation", 
                "Obesity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Presence of BE defined as \u2265 1 cm of visible columnar mucosa in the       distal\n             esophagus with intestinal metaplasia on histology.\n\n          -  Absence of high grade dysplasia or EAC on baseline histology.\n\n          -  BMI > 30 kg/m2 or Waist circumference > 102 cm in men, > 88 cm in women.\n\n          -  Ability to give informed consent.\n\n        Exclusion Criteria\n\n          -  Allergy to \u03c93 FFAs, fish or shellfish.\n\n          -  Presence of high grade dysplasia or cancer on histology.\n\n          -  Pregnant and or breastfeeding women\n\n          -  Presence of esophagitis on initial endoscopy or symptoms of refractory GERD\n             (heartburn or regurgitation \u2265 2 times a week) indicative of uncontrolled\n             gastroesophageal reflux.\n\n          -  Inability to give informed consent.\n\n          -  Currently taking Omega3 FFA as prescription or as supplement.\n\n          -  Anti-coagulant therapy (Plavix, Warfarin, Coumadin)\n\n          -  AST or ALT level > three times upper limit of normal at baseline\n\n          -  LDL > 200 mg/dl at baseline.\n\n          -  INR > 2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733147", 
            "org_study_id": "12-005914"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3 free fatty acids", 
                "description": "Subjects with Barrett's esophagus. Baseline assessment: measure waist and hip circumference, height, weight. Complete the Reflux Symptom Questionnaire (RSQ). 10cc of blood drawn after 12 hour fast for serum free fatty acid (FFA) profile. Clinical baseline blood drawn: INR, LDL, AST and ALT. Endoscopy performed: four biopsies obtained from the GE junction and 4 biopsies from the BE mucosa. Randomized to \u03c93 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects (presence and grade) and reinforce compliance. Compliance will also be assessed by pill counts during monthly call. Subjects will undergo repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a fasting blood draw for serum FFA profile, LDL, AST, ALT, INR and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the Reflux Symptom Questionnaire (RSQ).", 
                "intervention_name": "Omega-3 free fatty acids", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DHA/EPA", 
                    "Omega-3 fatty acid ethyl esters", 
                    "Ocean Blue\u00ae Professional Omega-3 2100\u2122"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects with Barrett's esophagus. Baseline assessment: measure waist and hip circumference, height, weight. Complete the Reflux Symptom Questionnaire (RSQ). 10cc of blood drawn after 12 hour fast for serum free fatty acid (FFA) profile. Clinical baseline blood drawn: INR, LDL, AST and ALT. Endoscopy performed: four biopsies obtained from the GE junction and 4 biopsies from the BE mucosa. Randomized to \u03c93 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects (presence and grade) and reinforce compliance. Compliance will also be assessed by pill counts during monthly call. Subjects will undergo repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a fasting blood draw for serum FFA profile, LDL, AST, ALT, INR and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the Reflux Symptom Questionnaire (RSQ).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Barrett's esophagus", 
            "Obesity", 
            "Omega-3 fatty acid"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Modulation of Esophageal Inflammation in Barrett&Apos;s Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Prasad Iyer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Specific Aim 1: To estimate the magnitude and variation of changes in esophageal inflammation and injury in Barrett's esophagus as measured by tissue PGE2 and the esophageal inflammation score, attributable to \u03c93 FFA supplementation.", 
            "measure": "changes in esophageal inflammation", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733147"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Prasad G. Iyer", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Specific Aim 2: To estimate the magnitude and variation of changes in esophageal macrophage infiltration and modulation of esophageal macrophage phenotype attributable to \u03c93 FFA supplementation.", 
            "measure": "variation of changes in esophageal tissue", 
            "safety_issue": "No", 
            "time_frame": "baseline and 6 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}